

Northern Territory of Australia

Medicines, Poisons and Therapeutic Goods Act 2012

Approval: The Royal Flying Doctor Service – Western Operations

I, Christopher Paul Burgess, Chief Health Officer:

- (a) under section 254(1) of the *Medicines, Poisons and Therapeutic Goods Act 2012* (***the Act***), approve each Scheduled substance treatment protocol specified in Schedule A, and
- (b) under section 254(3) of the Act, state that each Schedule Substance Treatment Protocol specified in Schedule A remains in effect for a period of 2 years on and from the date of this Notice.

Dated 18/09/2026

Chief Health Officer

Schedule A

Title	Publication Date	Author
The Royal Flying Doctor Service Western Operations - SSTP	18 September 2026	Medicines and Poisons Northern Territory Government, NT Health

Royal Flying Doctor Service of Australia (Western Operations) - SSTP

Areas Applicable	INPEX Ichthys LNG – Wickham	
Health Professionals authorised by this SSTP	Nurses and Paramedics employed by or contracted to Royal Flying Doctor Service of Australia (Western Operations) - ABN 29 067 077 696	
Scheduled Substance(s)	Schedule 3 & 4 Medicines	
	Adenosine	Metaraminol
	Adrenaline (epinephrine)	Methoxyflurane
	Amiodarone	Metoclopramide
	Amoxicillin	Metronidazole
	Atropine	Midazolam
	Cefalexin	Naloxone
	Ceftriaxone	Naproxen
	Clavulanic Acid	Ondansetron
	Clopidogrel	Prednisolone
	Codeine - when compounded with paracetamol into individual dose forms	Promethazine
	Dexamethasone	Roxithromycin
	Diazepam	Salbutamol
	Diclofenac	Silver Sulfadiazine
	Enoxaparin	Tranexamic Acid
	Flucloxacillin	Vaccine - Diphtheria
	Framycetin	Vaccine - Hepatitis A
	Furosemide	Vaccine - Hepatitis B
	Glucagon	Vaccine - Influenza
	Glyceryl Trinitrate	Vaccine - Tetanus
	Gramicidin	
	Hydrocortisone	Schedule 8 Medicines
	Hyoscine Butylbromide	Fentanyl
	Ipratropium	Ketamine
	Lidocaine	Morphine

Indication, Dose, Route, Frequency	- Individual substances, or combinations of substances, are to be used according to the indication for which they are being administered as outlined in RFDS-WO Medication Management Policy (CLN 53) as in force from time to time. - Any administration of these substances outside of the approved Guidelines must be under direct instruction of a Medical Practitioner.		
Contraindications and/or Exclusions*	- Hypersensitivity or allergy to the individual drug substance or excipients of that formulation of the listed scheduled substances of this protocol. - Any contraindications or exclusions as outlined in the individual scheduled substance product information. - Any contraindication or exclusions as outlined in RFDS-WO Medication Management Policy (CLN 53) as in force from time to time.		
Health Professional Accreditation Requirements	<u>Nurses must:</u> - Hold registration with the Nursing and Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients - Maintain continuing professional development related to skills and competencies required for delivery of medicines <u>Paramedics must:</u> - Hold registration with the Paramedicine Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients - Maintain continuing professional development related to skills and competencies required for delivery of medicines		
Chief Health Officer	Signature	Name	Date
	09-D26-71321	Paul Burgess	18/09/2026
Period of effect	This SSTP is in effect until 18/09/2028 unless revoked earlier		
References: * The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer’s product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration			